February 26, 2018 / 11:31 AM / 7 months ago

BRIEF-Achillion Announces ACH-4471 Receives Positive Opinion For Orphan Drug Status In EU For The Treatment Of C3 Glomerulopathy

Feb 26 (Reuters) - Achillion Pharmaceuticals Inc:

* ACHILLION ANNOUNCES ACH-4471 RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR THE TREATMENT OF C3 GLOMERULOPATHY

* ACHILLION - ‍EMA COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS ISSUED POSITIVE OPINION ON ACH-4471 FOR ORPHAN STATUS IN EU FOR C3 GLOMERULOPATHY​ TREATMENT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below